Red Light Holland, in Partnership with FDA-Compliant and DEA-Registered Irvine Labs, Updates R&D Plan Focused On Commercialization
Red Light Holland (TRUFF) has announced a research and development partnership with Irvine Labs, an FDA-compliant and DEA-registered facility in California. The collaboration focuses on developing improved preservation techniques for psilocybin products, specifically targeting extended shelf life for naturally derived psilocybin microdosing capsules.
Irvine Labs has applied for its 2025 Psilocybin DEA quota for import and will begin testing new proprietary dehydration and packaging techniques once they receive raw materials from Red Light Holland's Netherlands farm. The partnership aims to enhance product stability and quality throughout the supply chain, with the goal of expanding into global emerging legal markets, government-funded pilot programs, and clinical trials worldwide.
The initiative combines Irvine Labs' expertise in manufacturing and compliance with Red Light Holland's natural psilocybin products to overcome preservation challenges in product development and manufacturing.
Red Light Holland (TRUFF) ha annunciato una partnership di ricerca e sviluppo con Irvine Labs, una struttura conforme alla FDA e registrata presso la DEA in California. La collaborazione si concentra sullo sviluppo di tecniche di conservazione migliorate per i prodotti a base di psilocibina, con l'obiettivo specifico di prolungare la durata di conservazione delle capsule di microdosaggio di psilocibina di origine naturale.
Irvine Labs ha presentato la propria domanda per il contingente DEA per la psilocibina del 2025 per l'importazione e inizierà a testare nuove tecniche proprietarie di disidratazione e confezionamento non appena riceverà le materie prime dalla fattoria di Red Light Holland nei Paesi Bassi. La partnership mira a migliorare la stabilità e la qualità del prodotto lungo tutta la catena di approvvigionamento, con l'obiettivo di espandersi nei mercati legali emergenti a livello globale, nei programmi pilota finanziati dal governo e negli studi clinici in tutto il mondo.
L'iniziativa combina l'expertise di Irvine Labs nella produzione e conformità con i prodotti naturali di psilocibina di Red Light Holland per affrontare le sfide di conservazione nello sviluppo e nella produzione dei prodotti.
Red Light Holland (TRUFF) ha anunciado una asociación de investigación y desarrollo con Irvine Labs, una instalación conforme a la FDA y registrada en la DEA en California. La colaboración se centra en el desarrollo de técnicas de conservación mejoradas para productos de psilocibina, específicamente apuntando a una vida útil prolongada para las cápsulas de microdosificación de psilocibina derivadas de manera natural.
Irvine Labs ha solicitado su cuota DEA de psilocibina para 2025 para importación y comenzará a probar nuevas técnicas propietarias de deshidratación y envasado una vez que reciba las materias primas de la granja de Red Light Holland en los Países Bajos. La asociación tiene como objetivo mejorar la estabilidad y calidad del producto a lo largo de la cadena de suministro, con el objetivo de expandirse en mercados legales emergentes globales, programas piloto financiados por el gobierno y ensayos clínicos en todo el mundo.
La iniciativa combina la experiencia de Irvine Labs en fabricación y cumplimiento con los productos naturales de psilocibina de Red Light Holland para superar los desafíos de conservación en el desarrollo y fabricación de productos.
Red Light Holland (TRUFF)는 캘리포니아에 있는 FDA 인증 및 DEA 등록 시설인 Irvine Labs와 연구 및 개발 파트너십을 발표했습니다. 이 협력은 자연에서 유래된 psilocybin 미세복용 캡슐의 유통 기한 연장을 목표로 하여 psilocybin 제품에 대한 향상된 보존 기술을 개발하는 데 중점을 두고 있습니다.
Irvine Labs는 2025년 psilocybin DEA 할당량 수입을 신청했으며, Red Light Holland의 네덜란드 농장에서 원자재를 받는 즉시 새로운 독점 탈수 및 포장 기술을 테스트할 예정입니다. 이 파트너십은 공급망 전반에 걸쳐 제품의 안정성과 품질을 향상시키는 것을 목표로 하여, 글로벌 신생 합법 시장, 정부 자금 지원 파일럿 프로그램 및 전세계 임상 시험으로의 확장을 계획하고 있습니다.
이 이니셔티브는 제품 개발 및 제조에서 보존과 관련된 문제를 해결하기 위해 Red Light Holland의 자연 psilocybin 제품과 Irvine Labs의 제조 및 규정 준수 전문성을 결합합니다.
Red Light Holland (TRUFF) a annoncé un partenariat de recherche et développement avec Irvine Labs, une installation conforme à la FDA et enregistrée auprès de la DEA en Californie. La collaboration se concentre sur le développement de techniques de conservation améliorées pour les produits à base de psilocybine, visant spécifiquement à prolonger la durée de conservation des capsules de microdosage de psilocybine d'origine naturelle.
Irvine Labs a demandé son quota DEA pour la psilocybine pour 2025 pour l'importation et commencera à tester de nouvelles techniques propriétaires de déshydratation et d'emballage dès qu'ils recevront des matières premières de la ferme de Red Light Holland aux Pays-Bas. Le partenariat vise à améliorer la stabilité et la qualité des produits tout au long de la chaîne d'approvisionnement, avec pour objectif de s'étendre sur les marchés légaux émergents à l'échelle mondiale, les programmes pilotes financés par le gouvernement et les essais cliniques dans le monde entier.
L'initiative combine l'expertise d'Irvine Labs en matière de fabrication et de conformité avec les produits naturels de psilocybine de Red Light Holland pour surmonter les défis de conservation dans le développement et la fabrication des produits.
Red Light Holland (TRUFF) hat eine Forschungs- und Entwicklungspartnerschaft mit Irvine Labs, einer von der FDA zugelassenen und bei der DEA registrierten Einrichtung in Kalifornien, bekannt gegeben. Die Zusammenarbeit konzentriert sich auf die Entwicklung verbesserter Konservierungstechniken für Psilocybin-Produkte, wobei gezielt eine längere Haltbarkeit für auf natürliche Weise gewonnene Psilocybin-Mikrodosierungskapseln angestrebt wird.
Irvine Labs hat seine DEA-Quote für Psilocybin für 2025 zur Einfuhr beantragt und wird mit dem Test neuer proprietärer Dehydrierungs- und Verpackungstechniken beginnen, sobald sie die Rohstoffe von der Farm von Red Light Holland in den Niederlanden erhalten. Ziel der Partnerschaft ist es, die Produktstabilität und -qualität entlang der gesamten Lieferkette zu verbessern, mit dem Ziel, in aufstrebende globale Legalmärkte, staatlich geförderte Pilotprogramme und klinische Studien weltweit zu expandieren.
Die Initiative vereint die Expertise von Irvine Labs in der Herstellung und Compliance mit den natürlichen Psilocybin-Produkten von Red Light Holland, um die Herausforderungen der Konservierung in der Produktentwicklung und -herstellung zu überwinden.
- Partnership with FDA-compliant and DEA-registered facility enhances regulatory compliance
- Development of proprietary preservation technology could extend product shelf life
- Potential expansion into global emerging legal markets and clinical trials
- Access to certified GMP manufacturing capabilities through Irvine Labs
- Project depends on pending DEA quota approval
- Success of preservation technology not yet proven
- Timeline for commercialization remains uncertain
Toronto, Ontario--(Newsfile Corp. - January 30, 2025) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland" or the "Company"), an Ontario-based corporation engaged in the production, growth, and sale of functional mushrooms and mushroom home grow kits in North America and Europe, as well as a premium brand of psilocybin truffles in the legal, recreational market within the Netherlands, in compliance with all applicable laws is excited to announce details of its research and development plan with their partner, Irvine Labs Inc. ("Irvine Labs"), an FDA-compliant and DEA-registered facility in California.
Red Light Holland's new partner, Irvine Labs is licensed for prescription and over-the-counter (OTC) drug manufacturing by the California Department of Public Health (CDPH) and is a DEA Schedule 1 Bulk drug cultivator, manufacturer, importer and exporter; including psilocybin, psilocin, marijuana, THC, extracts, DET, DMT, LSD, peyote and mescaline.
Updated Plan:
- Irvine Labs has applied for its initial 2025 Psilocybin DEA quota for import.
- Testing of new proprietary dehydration and packaging techniques aimed at extending product shelf life will commence after Irvine Labs obtains the necessary quota and receives raw materials from Red Light Holland's Netherlands farm.
- Increasing product shelf life, along with Irvine Lab's ability to export, will increase the potential of commercialization and sales to emerging legal markets, government funded pilot programs and clinical trials worldwide.
"We are very excited about this R&D plan we developed with Irvine Labs, to extend the shelf life of our naturally derived psilocybin microdosing capsule," said Todd Shapiro, CEO and Director of Red Light Holland. "Irvine Labs is an ideal partner as we push to expand into global emerging legal markets. Their certified GMP, FDA-compliant and DEA-registered lab will help ensure we have the highest quality products that will help with our ultimate aim of distribution and commercialization. We are closely following the potential appointment of Robert F. Kennedy Jr., in his bid to lead the U.S. Department of Health and Human Services as we believe (and applaud) he demonstrates signs of openness to alternative and naturally derived therapeutic approaches. We look forward to a hopeful promising landscape for innovative mental health solutions and want to be ready with the best products."
Shaun Land, President of Irvine Labs, added, "We have extensive experience working with naturally derived pharmaceutical ingredients and are excited to support Red Light Holland's microdosing program with our expertise in manufacturing and compliance, aiming to extend these innovative products stability and shelf life."
"As we continue to develop our microdosing capsules, which are intended for legal emerging markets and clinical trials around the world, it is important they have an increased shelf life," added Red Light Holland's CTIO, Sarah Hashkes.
The preservation of psilocybin from naturally derived compounds presents unique challenges in product development and manufacturing. Through Red Light Holland's partnership with Irvine Labs and the implementation of proprietary preservation technology, Red Light Holland aims to overcome these challenges by developing precise dehydration, manufacturing and storage protocols that maintain the integrity of natural compounds while significantly extending product shelf life. Combined with research into advanced packaging solutions, these innovations represent a comprehensive approach to ensuring product stability and quality throughout the supply chain.
Once Irvine Labs receives their expected initial 2025 psilocybin quota and finishes setting up of new lab equipment, they will submit the import permit necessary to receive Red Light Holland's natural psilocybin products, grown in the company's farm in the Netherlands. Upon receiving the hopeful shipment, Irvine Labs will begin testing their proprietary dehydration and packaging solutions.
Red Light and Irvine Labs combined goal is to develop a commercialized product that can be legally exported to emerging markets and used in government-funded pilot programs and clinical trials within the United States.
About Irvine Labs
Irvine Labs was established in 1997. Since 2013, Irvine Labs has had a significant investment in medical research and development through its Pharmaceutical Biotechnology Division with a focus on natural medicines, including cannabis, cannabinoids, psilocybin, herbs and other sources of natural medicines. Irvine Labs is licensed for Prescription and Over-the-Counter (OTC) drug manufacturing by the California Department of Public Health (CDPH). Irvine Labs is a DEA Schedule 1 Bulk drug manufacturer, importer and exporter (including marijuana, THC, extracts, psilocybin, psilocin, DET, DMT, LSD, Peyote and Mescaline, and Schedule 1-5 testing lab.
About Red Light Holland
Red Light Holland is an Ontario-based corporation engaged in the production, growth and sale of functional mushrooms and mushroom home grow kits in North America and Europe, and a premium brand of psilocybin truffles to the legal, recreational market within the Netherlands, in compliance with all applicable laws.
For additional information on the Company:
Todd Shapiro
Chief Executive Officer & Director
Tel: 647-643-TRIP (8747)
Email: todd@redlight.co
Website: www.RedLight.co
Forward-Looking Statements and Cautionary Note
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company's current belief or assumptions as to the outcome and timing of such future events.
The forward-looking information and forward-looking statements contained herein include, but are not limited to, statements regarding: the Company's performance, business objectives and milestones and the anticipated timing thereof, and costs in connection with, the execution or achievement of such objectives and milestones, including its plans to continue seeking legal opportunities to increase responsible access to natural psilocybin around the world and Irvine lab's development of the Company's psilocybin; the Company and the Company's partners to maintain its stated licenses and obtain all necessary additional licenses and regulatory approval required for the Company to carry out its plans as described; the expectations with respect to the Company's next psilocybin import, Irvine lab's DEA approval of initial 2025 psilocybin quota; the Company's continued commitment towards ensuring legal, responsible access to Red Light's standardized natural psilocybin products; the Company's commitment to making further announcements with respect to its overall R&D project, including its partnership with Irvine Labs Inc. and the research project to develop a process for the commercial manufacture of microdosing capsules derived from the Company's psilocybin truffles; the Company proving out potential therapeutic benefits of Psilocybin; the Company receiving important insights from naturally occurring psilocybin truffles; the Company's ability to extract and expand access to psilocybin products; and the Company's ability to scalable production of high-quality, and approved microdoing capsules with extended shelf life via Irvine Labs ability to export their manufactured products from the United States to emerging markets, or sell to government funded pilot programs or clinical trials in the United States or around the world.
Forward-Looking information in this press release are based on certain assumptions and expected future events, namely: the Company's ability to maintain or exceed its current performance, and carry out its business objectives and milestones and under the anticipated timing and costs in connection with, the execution or achievement of such objectives and milestones; the Company and the Company's partners' abilities, including Irvine Labs to maintain its stated licenses and obtain all necessary additional licenses and regulatory approval required for the Company to carry out its plans as described; the Company's ability to realize its plans for future approved psilocybin imports Irvine lab's DEA approval of initial 2025 psilocybin quota; the Company's ability for its continued commitment towards ensuring legal, responsible access to Red Light's standardized natural psilocybin products; the Company's ability to maintain its commitment to making further announcements with respect to its overall R&D project, including its partnership with Irvine Labs and their research project to develop a process for the commercial manufacture of natural-source microdoing capsules derived from the Company's psilocybin truffles; the Company proving out potential therapeutic benefits of Psilocybin; the Company receiving important insights from naturally occurring psilocybin truffles; the ability to extract and expand access to psilocybin products; and the Company's ability to have scalable production of high-quality, microdosing capsules with extended shelf life for Global Distribution and The Company's ability to import their products into the United States and eventually the Companys ability to export their manufactured products from the United States to emerging markets, or sell to government funded pilot programs or clinical trials in the us or around the world.
These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to: the Company's inability to maintain or exceed its current performance, and carry out its business objectives and milestones and under the anticipated timing and costs in connection with, the execution or achievement of such objectives and milestones; the Company and the Company's partners' inabilities, including Irvine Labs, to maintain its stated licenses and obtain all necessary additional licenses and regulatory approval required for the Company to carry out its plans as described; the Company's inability to realize upon its plans for its aimed approved psilocybin import; the Company's inability to maintain its commitment towards ensuring legal, responsible access to Red Light's standardized natural psilocybin products; the Company's inability to maintain its commitment to making further announcements with respect to its overall R&D project, including its partnership with Irvine Labs; and The Company's ability to expand and extract access to psilocybin products.
The Company cannot make medical claims and is purely in a R&D phase with its partners Irvine Labs Inc.
Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
Forward-Looking statements contained in this press release are expressly qualified by this cautionary statement and reflect the Company's expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/238943
FAQ
What is the purpose of Red Light Holland's partnership with Irvine Labs for TRUFF stock?
When will Irvine Labs begin testing Red Light Holland's psilocybin products?
What markets is Red Light Holland (TRUFF) targeting with this R&D initiative?
How will the Irvine Labs partnership affect TRUFF's product development?
